Ciba-geigy Corporation

Novartis Ag

Novartis Corporation

Novartis Pharma Gmbh

Pascal Rigollier

Peter Herold

Stefan Stutz

Nissim Claude Cohen

Walter Schilling

Yasuchika Yamaguchi

Richard Goschke

J Urgen Maibaum

Richard G Oschke

Robert Mah

Bo Tong Liu

Jiping Fu

Andrea Vaupel

Trixi Brandl

Jurgen Klaus Maibaum

Rainer Machauer

Catherine Leblanc

David Thomas Parker

Aregahegn Yifru

Marc Gerspacher

Prakash Raman

Oliver Simic

Mohindra Seepersaud

Rui Zheng

Edwige Liliane Jeanne Lorthiois

Simona Cotesta

Branko Radetich

Francois Lenoir

Rainer Wilcken

Christophe Mura

Nadine Schneider

Nicolas Warin

The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Pyrazolyl derivatives useful as anti-cancer agents

.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.

Azido containing tetrahydro furan compounds

.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acids

.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1##

.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides

Compounds of formula I ##STR1## wherein R.sub.1 is a 2-R.sub.A -3-R.sub.B -phenyl radical, a 2-R.sub.A -4-R.sub.C -phenyl radical, a 2-R.sub.A -pyridin-3-yl radical, a 3-R.sub.A -pyridin-2-yl radical or a 1-R.sub.D -indol-3-yl radical, wherein one of the radicals R.sub.A and R.sub.B is an aliphatic or heterocycloaliphatic-aliphatic radical or free or aliphatically, araliphatically or heteroaraliphatically etherified hydroxy and the other is hydrogen, an aliphatic radical or free or esterified or amidated carboxy, R.sub.C is hydrogen, an aliphatic radical, free or aliphatically, araliphatically, heteroaraliphatically or heteroarylaliphatically etherified hydroxy or an unsubstituted or heteroaliphatically substituted amino group, and R.sub.D is an aliphatic, araliphatic or heteroaliphatic radical, one of the radicals X.sub.1 and X.sub.2 is carbonyl and the other is methylene, R.sub.2 is an aliphatic radical, R.sub.3 is unsubstituted or aliphatically substituted amino, R.sub.4 is an aliphatic or araliphatic radical, and R.sub.5 is an aliphatic or cycloaliphatic-aliphatic radical or an optionally hydrogenated and/or oxo-substituted heteroaryl radical or an optionally hydrogenated and/or oxo-substituted heteroaryl or heteroaliphatyl radical bonded via a carbon atom, and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive active ingredients of medicaments.

Aromatically substituted .omega.-amino-alkanoic acid amides and alkanoic

Compounds of formula I ##STR1## wherein R.sub.1 is free or esterified carboxy, hydroxymethyl or formyl,

3,5-Disubstituted tetrahydrofuran-2-ones

Growing community of inventors

Sierentz, France

Pascal Rigollier